Diabetes Archives

News and Trends 1 Jul 2015

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin absorption. The study aimed to compare BioChaperone Lispro to Lilly’s Humalog in type 1 diabetes patients, the former being much more effective. Humalog, Lilly’s blockbuster, is about to be ousted by Adocia’s insulin absorption accelerator. BioChaperone Lispro […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

diabetes type 2 sanofi novo nordisk eli lilly

News and Trends 11 Jun 2015

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things come to those who wait. After years of delay, the French colossus is convinced with the Phase IIIb results on its type 2 diabetes treatment. […]

June 11, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 May 2015

Poxel is Looking towards Japan’s Lucrative Diabetes Market

Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate. Imeglimin has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU and is ready for Phase III. This […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 17 May 2015

The Miracle Berry which Hacks your Taste Buds to Replace Sugar

Can you name a fruit capable of disturbing your taste buds? For up to two hours, the red miracle berry can transform sour foods like lemon or vinegar, in an amazing sweet taste. It’s a very interesting berry because of its non-caloric property for anti-obesity and anti-diabetes use. This miracle berry that grows in West Africa contains Miraculin, […]

May 17, 2015 - 3 minutesmins - By Julie Lellouche

News and Trends 3 May 2015

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as a public company. Imeglimin, its lead candidate, is a Type 2 diabetes treatment (licensed by Merck Serono) on the launch of Phase III. This innovative compound is […]

May 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Apr 2015

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Last week, FDA expressed its concerns about AstraZeneca’s treatment for type 2 diabetes, Onglyza. According to Reuters, FDA found “significant or near significant” increase of death risk. However, the agency also admits that the cause of death is multifactorial and could not be directly related to AstraZeneca’s treatment. The drug was developed as a result […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Mar 2015

Orgenesis acquires MaSTherCell

Orgenesis acquired MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics based in Gosselies, Belgium, as part of the American company’s plan to increase its global presence and capabilities. The American and the Belgian companies have already been working jointly since last year to scale manufacturing of Orgenesis’ insulin-producing liver cells to fight diabetes. […]

March 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Feb 2015

Sanofi: Get Ready for the Launch of the First Inhaled Insulin in the U.S.

Sanofi, the global healthcare leader has core strengths in the field of healthcare due to its seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. This article will focus on Sanofi Diabetes. In August 2014, our previous article “Sanofi buys Mannkind’s inhaled insulin for €824.5m” […]

February 27, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Feb 2015

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

Good news for diabetes mellitus type 2 patients, as Novo Nordisk announced positive results for phase II trial with oral semaglutide. Novo Nordisk successfully completed the phase II trial for OG217SC, an oral formulation of the longacting GLP-1 analogue semaglutide. Confirming the primary end-point of the trial, all doses of oral semaglutide were statistically significantly […]

February 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Nov 2014

Novo Nordisk invests €104M in new laboratory for Diabetes

Danish insulin giant Novo Nordisk has made a 104 million euros investment in new laboratories at the company’s research and development campus. Based in Malov in Denmark, the lab is expected to be ready for occupation in early 2016. The new facility, Diabetes Research House, will accommodate approximately 350 employees. During the construction phase, the project […]

November 4, 2014 - 1 minutemin - By Julie Lellouche

Oral Insulin All Mouth or an Injection of Hope for Type 1 Diabetes medium vga

News and Trends 8 Oct 2014

Once a Week Insulin Shot : Novo Nordisk’s new Idea

Denmark’s Novo Nordisk, the world’s largest insulin seller, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world’s first once-weekly insulin injection. Almost 592 million people are expected to live with diabetes by 2035, up 55 percent from last year’s level, according to the International Diabetes […]

October 8, 2014 - 2 minutesmins - By Julie Lellouche

Eli Lilly and Boehringer Ingelheim’s product the first insulin biosimilar approved in Europe2

News and Trends 16 Sep 2014

The first insulin biosimilar has been approved in Europe

The European Commission granted marketing authorisation to Eli Lilly and Company and Boehringer Ingelheim for the first insulin biosimilar glargine product. It is indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The collaboration between the two companies is bearing fruit, it is the first-ever version of this class. It received […]

September 16, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Diabetes

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

Poxel is Looking towards Japan’s Lucrative Diabetes Market

The Miracle Berry which Hacks your Taste Buds to Replace Sugar

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Orgenesis acquires MaSTherCell

Sanofi: Get Ready for the Launch of the First Inhaled Insulin in the U.S.

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

Novo Nordisk invests €104M in new laboratory for Diabetes

Once a Week Insulin Shot : Novo Nordisk’s new Idea

The first insulin biosimilar has been approved in Europe

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!